Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

VIKING THERAPEUTICS Aktie

 >Aktienkurs 
29.9 EUR    +2.2%    (TradegateBSX)
Ask: 30.05 EUR / 100 Stück
Bid: 30 EUR / 100 Stück
Tagesumsatz: 1198 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: +7,4%
1 Monat: +5,3%
3 Monate: +15,2%
6 Monate: +7,5%
1 Jahr: +32,3%
laufendes Jahr: -4,1%
>VIKING THERAPEUTICS Aktie
Name:  VIKING THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US92686J1060 / A12GD6
Symbol/ Ticker:  1VT (Frankfurt) / VKTX (NASDAQ)
Kürzel:  FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX
Index:  -
Profil:  Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being s..
>Volltext..
Marktkapitalisierung:  3389.85 Mio. EUR
Unternehmenswert:  2953.97 Mio. EUR
Umsatz:  -
EBITDA:  -482.94 Mio. EUR
Nettogewinn:  -461.56 Mio. EUR
Gewinn je Aktie:  -4.02 EUR
Schulden:  3.53 Mio. EUR
Liquide Mittel:  108.53 Mio. EUR
Operativer Cashflow:  -361.14 Mio. EUR
Bargeldquote:  4.57
Umsatzwachstum:  -
Gewinnwachstum:  -221.56%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  VIKING THERAPEUTICS, VIKING THERAPEUTIC
Letzte Datenerhebung:  06.09.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 116.65 Mio. St.
Frei handelbar: 96.81%
Rückkaufquote: -0.08%
Mitarbeiter: 53
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 177.83%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 9.46
PEG-Ratio: -0.03
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -79.24%
Eigenkaprendite: -88.85%
>Peer Group
Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Endokrine Erkrankungen (Hormonstörungen), Stoffwechselerkrankungen (Diabetes/ Adipositas)
 
06.09.26 - 02:36
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here′s the Skeptics′ Case. (Fool)
 
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company....
04.09.26 - 01:00
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know (Zacks)
 
Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day....
03.09.26 - 23:00
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here′s Why I Think They′re Wrong (Fool)
 
Viking Therapeutics deserves a second look, but some analysts are a bit too optimistic....
30.08.26 - 22:24
Viking Therapeutics Stock Is Down 66% From Its Peak. Here′s What Comes Next. (Fool)
 
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate....
27.08.26 - 17:12
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? (Fool)
 
Investor sentiment on the key benefit of its lead drug candidate could be impacted in the current quarter....
08.08.26 - 22:00
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? (Fool)
 
It's not much of a rivalry yet....
06.08.26 - 16:48
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished (Fool)
 
In a slow news month for the company, investors focused on the cost of its phase 3 trials rather than their benefits....
31.07.26 - 01:00
Vertex Just Paid $10 Billion for Crinetics. Here′s Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target (Fool)
 
There are other reasons to pay attention to Viking Therapeutics....
30.07.26 - 20:30
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs (Zacks)
 
Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline....
30.07.26 - 05:01
Insiderhandel: Chief Operating Officer verkauft Aktien von Viking Therapeutics im Wert von 609636 USD (Insiderkauf)
 
Mancini, Marianna - Vorstand - Tag der Transaktion: 2026-07-29...
30.07.26 - 05:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Viking Therapeutics im Wert von 710141 USD (Insiderkauf)
 
Zante, Greg - Vorstand - Tag der Transaktion: 2026-07-29...
30.07.26 - 05:01
Insiderhandel: President & CEO verkauft Aktien von Viking Therapeutics im Wert von 4947888 USD (Insiderkauf)
 
Lian, Brian - Vorstand - Tag der Transaktion: 2026-07-29...
29.07.26 - 22:15
Viking Therapeutics GAAP EPS of -$1.10 beats by $0.14 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.07.26 - 22:06
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
 
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin......
28.07.26 - 23:36
Wall Street Says Buy the Dip in Viking Therapeutics. Here′s the Bull Case (Fool)
 
The stock looks like a high-risk, high-reward play....
28.07.26 - 16:45
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
 
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...
28.07.26 - 16:33
Viking Therapeutics Q2 2026 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.07.26 - 01:00
Here′s Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market (Zacks)
 
Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close....
23.07.26 - 13:12
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors (PR Newswire)
 
Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel......
22.07.26 - 22:07
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 (PR Newswire)
 
Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ubi lex, ibi poena - Wo ein Gesetz, da auch eine Strafandrohung. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!